Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves

MONTREAL, May 05, 2021 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), whose primary mandate is to focus on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE) and wellness products, is pleased to provide an update on the performance of the exclusivity contract to supply medical examination gloves for North America.

On March 11, 2021 (see Press Release), Relevium announced the procurement and subsequent delivery of the first production batch of Personal Protective Equipment (“PPE”) from a Supply Agreement entered into during the last quarter of 2020 with 24 Clean Energy (the “Supplier”), a manufacturer and distributor of high-end medical grade nitrile gloves. The Company also announced it had obtained the “exclusive” North American rights to market the “DI-Line” brand of medical grade gloves, a much needed and sought-after PPE product.

The Thailand based supplier was to commence delivery of the first containers in the month of April 2021. Due to various issues relating to the COVID-19 pandemic, causing delays in the entire international supply chain cycle, the supplier has informed Relevium management to expect the first shipment to be delivered starting in the month of May, with the final delivery to its customers in the month of June.

The total number of units to be shipped to the port of Los Angeles is approximately 300,000 boxes (the First Phase) out of a total of 500,000 boxes (total order). The medical examination gloves are to be delivered to healthcare institutions in the United States, and form part of the initial launch of the suppliers “brand” into the North American market.

Aurelio Useche, CEO of Relevium stated: “We will continue to closely monitor the execution of this contract, and we expect to deliver a high-value product to our valued customer base. Our distribution partnership with H-Source Holdings provides the Company with access to Hospital Groups across the United States in a safe, highly efficient and complaint delivery platform, which we will continue to leverage as we enroll new clients into our program”.

About Relevium Technologies
Relevium Technologies Inc., is a publicly traded Company, focussed on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE) into the North American marketplace. Utilizing trusted vendors and suppliers, and integrating a comprehensive, state-of-the-art supply chain, Artificial Intelligence (“AI), and Blockchain technology, enables a highly secure and compliant platform for delivery of PPE equipment to Governments, Hospitals, Foundations, and various Institutions.  
Biocannabix Health Corporation, a wholly owned subsidiary of Relevium Technologies Inc., is focused on Paediatric and Geriatric applications of Cannabinoid nutraceutical and medical food formulations. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and cannabinoids.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals.

These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn